Wyeth Provides Financial Guidance for 2006

Sign Up Sign In

Biohealthmatics Centers

Home

Jobs Search

Career Center

Networking Center

Company Profiles

Knowledge Center

Industry News

Web Directory

Industry Books

Wyeth Provides Financial Guidance for 2006

Wyeth (NYSE:WYE) announced today that pro forma diluted earnings per share for 2006 is expected to be in the $2.97 to $3.07 range. This estimate is pro forma as it excludes any potential restructuring charges resulting from the Company's ongoing review of business processes and systems.

MADISON, N.J. -- Wyeth (NYSE:WYE) announced today that pro forma diluted earnings per share for 2006 is expected to be in the $2.97 to $3.07 range. This estimate is pro forma as it excludes any potential restructuring charges resulting from the Company's ongoing review of business processes and systems. The estimate includes the impact of accounting for stock options as required by Statement of Financial Accounting Standards (SFAS) 123R, Share-Based Payment.

The Company had previously announced a guidance range for 2005 of $2.80 to $2.90 pro forma diluted earnings per share, or $2.63 to $2.73 when including the impact of stock option expense. The 2005 estimate excludes the one-time impact from repatriation of foreign earnings under the American Jobs Creation Act as well as any restructuring charges resulting from the Company's ongoing review of business processes and systems. The Company expects that actual results for 2005 will slightly exceed the upper end of the range.

"This 2006 earnings projection represents an increase targeted at 10% over 2005," says Robert Essner, Chairman, President and Chief Executive Officer, Wyeth. "Our expectations for 2006 reflect solid ongoing operating performance driven both by revenue growth and cost control."

Net revenue for 2006 is expected to grow in the mid to upper single-digit range and gross margin is expected to be in the 71% to 73% range. Selling, general and administrative expenses are expected to increase at a low single- digit rate and research and development expenses are projected to increase at approximately the same rate as revenue. Interest expense is expected to be significantly higher than 2005 levels reflecting payments related to diet drug litigation. Other income is expected to decrease substantially as a result of lower royalty income and lower gains from product divestitures. The tax rate is expected to be approximately 22%.

The Company will hold a conference call with investors and research analysts at 5:30 p.m. Eastern Time today. The purpose of the call is to discuss earnings guidance. Interested investors and others may listen to the call live or on a delayed basis through the internet webcast, which may be accessed on the Company's Internet website at www.wyeth.com by clicking on the "Investor Relations" hyperlink. Also, for recent announcements and additional information, please refer to the Company's Internet website.

Other News Items Published on the Monday, January 09, 2006

Can't find what you are looking for? View our Site Map

Last Updated: 24 November 2007.